Literature DB >> 15145868

Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography.

J C C Moon1, N G Fisher, W J McKenna, D J Pennell.   

Abstract

OBJECTIVE: To investigate the role of cardiovascular magnetic resonance (CMR) in a series of patients with ECG repolarisation changes and normal echocardiography. PATIENTS AND
DESIGN: 10 patients with anterolateral T wave inversion for which there was no obvious pathological cause who had normal routine echocardiography without contrast for the exclusion of hypertrophic cardiomyopathy (HCM) also had CMR that was diagnostic of apical HCM.
RESULTS: Apical HCM detected by CMR could be morphologically severe with wall thickness up to 28 mm, or mild. The extent of repolarisation abnormalities did not correlate to the morphological severity.
CONCLUSIONS: In patients with unexplained repolarisation abnormalities, a normal routine echocardiogram without contrast does not exclude apical HCM. Further imaging with CMR or contrast echocardiography may be required. The reliance on routine echocardiography to exclude apical HCM may have led to underreporting of this condition.

Entities:  

Mesh:

Year:  2004        PMID: 15145868      PMCID: PMC1768283          DOI: 10.1136/hrt.2003.014969

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  26 in total

1.  Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy.

Authors:  K Prasad; J Atherton; G C Smith; W J McKenna; M P Frenneaux; P Nihoyannopoulos
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

2.  [Diagnosis of apical hypertrophic cardiomyopathy using contrast echocardiography].

Authors:  R Florenciano; J A Castillo; E Molina; P García Urruticoechea; S Egea; J Ortega
Journal:  Rev Esp Cardiol       Date:  2001-11       Impact factor: 4.753

3.  Long-term outcome in patients with apical hypertrophic cardiomyopathy.

Authors:  Maria J Eriksson; Brian Sonnenberg; Anna Woo; Paul Rakowski; Thomas G Parker; E Douglas Wigle; Harry Rakowski
Journal:  J Am Coll Cardiol       Date:  2002-02-20       Impact factor: 24.094

4.  Functional cardiac MR imaging with steady-state free precession (SSFP) significantly improves endocardial border delineation without contrast agents.

Authors:  H Thiele; E Nagel; I Paetsch; B Schnackenburg; A Bornstedt; M Kouwenhoven; A Wahl; G Schuler; E Fleck
Journal:  J Magn Reson Imaging       Date:  2001-10       Impact factor: 4.813

5.  Ventricular volume and mass by CMR.

Authors:  Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2002       Impact factor: 5.364

Review 6.  Apical hypertrophic cardiomyopathy (apical hypertrophy): an overview.

Authors:  T Sakamoto
Journal:  J Cardiol       Date:  2001       Impact factor: 3.159

7.  Morphological onset and early diagnosis in apical hypertrophic cardiomyopathy: a long term analysis with nuclear magnetic resonance imaging.

Authors:  J Suzuki; R Shimamoto; J Nishikawa; T Yamazaki; T Tsuji; F Nakamura; W S Shin; T Nakajima; T Toyo-Oka; K Ohotomo
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

8.  Novel insights into the natural history of apical hypertrophic cardiomyopathy during long-term follow-up.

Authors:  Edward G Abinader; Dawod Sharif; Arie Shefer; Johanan Naschitz
Journal:  Isr Med Assoc J       Date:  2002-03       Impact factor: 0.892

9.  Quantitative diagnosis of apical cardiomyopathy using contrast echocardiography.

Authors:  R Parker Ward; Lynn Weinert; Kirk T Spencer; Kathy T Furlong; James Bednarz; Jeanne DeCara; Roberto M Lang
Journal:  J Am Soc Echocardiogr       Date:  2002-04       Impact factor: 5.251

10.  Apical hypertrophic cardiomyopathy: bedside diagnosis by intravenous contrast echocardiography.

Authors:  P Soman; J Swinburn; M Callister; N G Stephens; R Senior
Journal:  J Am Soc Echocardiogr       Date:  2001-04       Impact factor: 5.251

View more
  96 in total

Review 1.  The role of magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Edward T D Hoey; Mohamed Elassaly; Arul Ganeshan; Richard W Watkin; Helen Simpson
Journal:  Quant Imaging Med Surg       Date:  2014-10

2.  MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors.

Authors:  Yasuo Amano; Mitsunobu Kitamura; Morimasa Takayama; Masaki Tachi; Shinichiro Kumita
Journal:  Int J Cardiovasc Imaging       Date:  2012-03-04       Impact factor: 2.357

3.  Asymmetric septal hypertrophic cardiomyopathy: a case report.

Authors:  Matt Rheinboldt; Chad Poopat
Journal:  Emerg Radiol       Date:  2010-11-23

4.  Eccentric apical hypertrophic cardiomyopathy unmasked by multimodality imaging: an uncommon but missed cause of out of hospital cardiac arrest.

Authors:  Eric Towe; Saurabh Sharma; Jeffrey Geske; Michael J Ackerman
Journal:  BMJ Case Rep       Date:  2015-07-06

Review 5.  Cardiac magnetic resonance in myocardial disease.

Authors:  U Sechtem; H Mahrholdt; H Vogelsberg
Journal:  Heart       Date:  2006-06-06       Impact factor: 5.994

Review 6.  Cardiovascular magnetic resonance and the evaluation of heart failure.

Authors:  James C C Moon; Sanjay K Prasad
Journal:  Curr Cardiol Rep       Date:  2005-01       Impact factor: 2.931

Review 7.  Recent developments in non-invasive cardiology.

Authors:  Sanjay K Prasad; Ravi G Assomull; Dudley J Pennell
Journal:  BMJ       Date:  2004-12-11

Review 8.  Clinical applications of cardiovascular magnetic resonance imaging.

Authors:  Constantin B Marcu; Aernout M Beek; Albert C van Rossum
Journal:  CMAJ       Date:  2006-10-10       Impact factor: 8.262

9.  Images in cardiology. Apical hypertrophic cardiomyopathy with apical aneurysm.

Authors:  Jon-David Schwalm; Mayraj Ahmad; Amin Mulji
Journal:  Can J Cardiol       Date:  2007-11       Impact factor: 5.223

10.  Cardiovascular magnetic resonance in the evaluation of heart failure.

Authors:  Ravi G Assomull; Dudley J Pennell; Sanjay K Prasad
Journal:  Heart       Date:  2007-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.